Colorectal Cancer

San Antonio, TX

136 Colorectal Cancer Trials near San Antonio, TX

Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

ABBV-400 vs Standard Treatment for Colorectal Cancer

Houston, Texas
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries. In stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

460 Participants Needed

Vaccine Nous-209 for Lynch Syndrome

Houston, Texas
This trial tests the safety and effectiveness of the Nous-209 vaccine in patients with Lynch syndrome, a condition that increases cancer risk. The vaccine uses man-made proteins to help the immune system recognize and fight cancer cells. Researchers aim to see if the vaccine can prevent cancer development in these high-risk patients. Nous-209 is a ready-to-use cancer vaccine that targets specific markers found in certain types of tumors.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

45 Participants Needed

LY3214996 + Cetuximab / Abemaciclib for Colorectal Cancer

Houston, Texas
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer that cannot be removed by surgery (unresectable) and/or has spread to other places in the body (metastatic). Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. LY3214996 and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LY3214996 and cetuximab alone or in combination with abemaciclib may help treat patients with colorectal cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

46 Participants Needed

Regorafenib + Lorigerlimab for Rectal Cancer

Houston, Texas
This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally recurrent pMMR/MSS localized rectal cancer following TNT.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

20 Participants Needed

Regorafenib + Lorigerlimab for Colorectal Cancer

Houston, Texas
To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2

30 Participants Needed

Regorafenib + Lorigerlimab for Colorectal Cancer

Houston, Texas
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

16 Participants Needed

Ivonescimab for Colorectal Cancer

Houston, Texas
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

90 Participants Needed

AMB-05X for Colorectal Cancer

Houston, Texas
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

15 Participants Needed

Adagrasib + Cetuximab + Cemiplimab for Colorectal Cancer

Houston, Texas
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

31 Participants Needed

AFNT-211 for Solid Tumors

Houston, Texas
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

A2B530 CAR T Therapy for Solid Cancers

Houston, Texas
This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

160 Participants Needed

EO4010 for Colorectal Cancer

Houston, Texas
Open-label multicenter study
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

42 Participants Needed

Cancer Vaccines for Lynch Syndrome

Houston, Texas
This trial tests a vaccine and an immune booster to prevent cancer in people with Lynch syndrome. The vaccine teaches the body to fight cancer, and the booster makes this process stronger. Vaccines have shown robust potential for preventing Lynch syndrome cancers.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

186 Participants Needed

Amivantamab + Chemotherapy for Colorectal Cancer

Houston, Texas
This trial is testing a new medicine called amivantamab on patients with advanced colorectal cancer. The medicine helps the immune system find and destroy cancer cells. Researchers want to see how well it works alone and with standard chemotherapy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

225 Participants Needed

TAS-102 for Colorectal Cancer

Houston, Texas
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

25 Participants Needed

Fecal Microbiota Transplant + Anti-PD-1 Therapy for Metastatic Colorectal Cancer

Houston, Texas
This phase II trial studies the effect of fecal microbiota transplant and re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) in treating anti-PD-1 non-responders with colorectal cancer that has spread to other places in the body (metastatic). Fecal microbiota transplants contain the normal bacteria and viruses found in fecal (stool) material. Immunotherapy with monoclonal antibodies, such as pembrolizumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab or nivolumab with fecal microbiota transplants may help to control the disease.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

15 Participants Needed

Why Other Patients Applied

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. Sheโ€™s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I had two chemotherapy regรญmens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this trรญal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've had radiation and as far as I know Iโ€™m in remission, but my brother passed away with the same condition. I donโ€™t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think itโ€™s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70
12345

Know someone looking for new options? Spread the word

Match to a Trial